𝔖 Bobbio Scriptorium

✦ LIBER ✦

T-Independent Activation of B Cells by Vesicular Stomatitis Virus: No Evidence for the Need of a Second Signal

✍ Scribed by Thomas Fehr; Martin F. Bachmann; Horst Bluethmann; Hitoshi Kikutani; Hans Hengartner; Rolf M. Zinkernagel

Book ID: 112239469
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 170 KB
Volume: 168
Category: Article
ISSN: 0008-8749
DOI: 10.1006/cimm.1996.0065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antigen-presenting B cells: Efficient up

Antigen-presenting B cells: Efficient uptake and presentation by activated B cells for induction of cytotoxic T lymphocytes against vesicular stomatitis virus

✍ Richard P. Ciavarra; David H. Burgess 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 983 KB

Evidence that induction of tolerance in

Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects Vβ8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B

✍ Peter Lane; Corinne Haller; Fiona McConnell 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 544 KB

Murine TRAIL (TNF-Related Apoptosis Indu

Murine TRAIL (TNF-Related Apoptosis Inducing Ligand) Expression Induced by T Cell Activation Is Blocked by Rapamycin, Cyclosporin A, and Inhibitors of Phosphatidylinositol 3-Kinase, Protein Kinase C, and Protein Tyrosine Kinases: Evidence for TRAIL Induction via the T Cell Receptor Signaling Pathway

✍ Bruce L. Musgrave; Tom Phu; Jared J. Butler; Andrew P. Makrigiannis; David W. Ho 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 126 KB

Efficacy of everolimus in second- and th

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).

✍ Buchler, Tomas; Bortlicek, Zbynek; Poprach, Alexandr; Kubackova, Katerina; Kiss, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 327 KB